Active substance
Multivitamins
- SFDA 9
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| CERNEVIT | Powder for solution for injection/infusion · Intravenous use | 10 Vial | SAR 215.30 | Generic · Prescription | BAXTER | Valid | |
| MIXAVIT SYRUP | 5 ml | Syrup · Oral use | 1 Bottle | SAR 9.95 | Generic · OTC | Gulf Pharmaceutical Industries (Julphar) | Valid |
| MIXAVIT TAB | Film-coated tablet · Oral use | 40 Tablet Container | SAR 6.10 | Generic · OTC | Gulf Pharmaceutical Industries (Julphar) | Valid | |
| MIXAVIT DROPS 15ML | Oral drops, solution · Oral use | 1 Bottle | SAR 4.95 | Generic · OTC | Gulf Pharmaceutical Industries (Julphar) | Withdrawn by MAH · Not Marketed | |
| NEUROTRAT FORTE TAB. | Tablet · Oral use | 20 Tablet Container | SAR 21.20 | Generic · OTC | Knoll Pharmaceuticals | Invalid · Not Marketed | |
| TRIHEMIC 600 MG TAB. | mg | Tablet · Oral use | 30 Tablet Container | SAR 17.85 | NCE · OTC | WYETH | Withdrawn by MAH · Not Marketed |
| VIDAYLIN DROPS | Oral drops, solution · Oral use | 1 Bottle | SAR 6.45 | Generic · OTC | Abbott Laboratories | Withdrawn by MAH · Not Marketed | |
| VIDAYLIN SYRUP | Syrup · Oral use | 1 Bottle | SAR 5.75 | Generic · OTC | Abbott Laboratories | Withdrawn by MAH · Not Marketed | |
| VIDAYLIN SYRUP | Syrup · Oral use | 1 Bottle | SAR 14.40 | Generic · OTC | Abbott Laboratories | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
BARIATRIC SURGERY; EPIDERMOLYSIS BULLOSA
Combinations containing Multivitamins
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.